Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT01515137 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Erlotinib
DRUG: Erlotinib plus sulindac
DRUG: Placebo

Sponsor

University of Pittsburgh

Collaborators

[object Object]